徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LH 徕博科

盘前交易 06-26 08:16:11 EDT

266.34

+1.16

+0.44%

盘前264.00

-2.20-0.83%

07:25 EDT

最高272.05	最低264.11	成交量58.23万
今开266.44	昨收265.18	日振幅2.99%
总市值219.46亿	流通市值219.46亿	总股本8,240万
成交额1.56亿	换手率0.71%	流通股本8,240万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LH","market":"US","secType":"STK","nameCN":"徕博科","latestPrice":266.34,"timestamp":1782417600000,"preClose":265.18,"halted":0,"volume":582307,"hourTrading":{"tag":"盘前","latestPrice":264,"preClose":266.199,"latestTime":"07:25 EDT","volume":4,"amount":1056.01,"timestamp":1782473121349,"change":-2.199,"changeRate":-0.008261,"amplitude":0.013787},"delay":0,"changeRate":0.004374387208688318,"floatShares":82400000,"shares":82400000,"eps":11.286123,"marketStatus":"盘前交易","change":1.16,"latestTime":"06-26 08:16:11 EDT","open":266.44,"high":272.05,"low":264.11,"amount":155513935.41640002,"amplitude":0.029942,"askPrice":288,"askSize":1,"bidPrice":228.25,"bidSize":41,"shortable":3,"etf":0,"ttmEps":11.286123,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782480600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":672379200000,"exchange":"NYSE","adjPreClose":266.199,"dividendRate":0.010813,"preHourTrading":{"tag":"盘前","latestPrice":264,"preClose":266.199,"latestTime":"07:25 EDT","volume":4,"amount":1056.01,"timestamp":1782473121349,"change":-2.199,"changeRate":-0.008261,"amplitude":0.013787},"postHourTrading":{"tag":"盘后","latestPrice":266.34,"preClose":266.34,"latestTime":"17:39 EDT","volume":82996,"amount":22105154.64,"timestamp":1782423551353,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8029074194323393,"impliedVol":0.2937,"impliedVolPercentile":0.76},"requestUrl":"/m/hq/s/LH","defaultTab":"news","newsList":[{"id":"1191592188","title":"徕博科宣布全美上市首款FDA批准基于RNA的居家结直肠癌筛查产品Colosense®","url":"https://stock-news.laohu8.com/highlight/detail?id=1191592188","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191592188?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126100,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）宣布，其首款获得美国食品药品监督管理局（FDA）批准的基于RNA技术的居家结直肠癌筛查检测产品Colosense®，现已在美国全国范围内上市。这款创新的非侵入性检测工具，标志着结直肠癌早期筛查领域的一次重要突破，为公众提供了更为便捷、私密的筛查选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","BK4550","LU0251142724.SGD","LU1059921491.USD","BK4585","LU2237438978.USD","LU0742534661.SGD","LH","BK4196","LU0006061336.USD","LU0048573561.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145365971","title":"Genfit携手Labcorp推出Nashnext®：基于Nis4®无创诊断技术，助力识别高危MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1145365971","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145365971?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:00","pubTimestamp":1780934421,"startTime":"0","endTime":"0","summary":"Genfit公司宣布，其基于自主研发的非侵入性诊断技术Nis4®所打造的Nashnext®检测方案，现已通过Labcorp（徕博科）的Ondemand服务正式推出。该产品旨在帮助识别存在代谢功能障碍相关脂肪性肝炎（MASH）风险的患者。\n此项合作标志着Genfit创新的无创诊断技术在临床可及性方面迈出了重要一步。通过Labcorp广泛的检测服务网络，医疗专业人员能够更便捷地利用Nashnext®，对高危人群进行早期筛查与风险评估，从而有望实现更及时的患者管理和干预。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0251142724.SGD","LH","BK4588","LU0048573561.USD","LU0251131958.USD","LU2237438978.USD","LU1059921491.USD","LU0742534661.SGD","BK4196","LU0006061336.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639102624","title":"Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2639102624","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639102624?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:29","pubTimestamp":1780054196,"startTime":"0","endTime":"0","summary":"Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌患者及其高危亲属的全国性、多中心大型临床试验。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300983","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","LU0048573561.USD","BK4196","LH","LU2237438978.USD","BK4550","LU0251131958.USD","BK4585","LU0006061336.USD","LU0251142724.SGD","LU0742534661.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169430590","title":"徕博科推出Mylabcorp™：一款AI驱动的移动应用，助力用户解读检验报告与追踪长期健康趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1169430590","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169430590?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:01","pubTimestamp":1779274893,"startTime":"0","endTime":"0","summary":"徕博科（Labcorp）近日正式发布了一款名为Mylabcorp™的全新移动应用程序。该应用由人工智能技术驱动，旨在帮助消费者更清晰地理解实验室检验结果，并长期追踪个人健康趋势的变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU0048573561.USD","LU0742534661.SGD","LU0251142724.SGD","LU2237438978.USD","BK4550","LH","BK4588","BK4585","LU0006061336.USD","LU1059921491.USD","LU0251131958.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176340925","title":"徕博科与Epic深化合作，推动医院及医疗系统诊断整合","url":"https://stock-news.laohu8.com/highlight/detail?id=1176340925","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176340925?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:02","pubTimestamp":1778583779,"startTime":"0","endTime":"0","summary":"徕博科与Epic系统公司宣布扩大合作范围，旨在共同推进诊断服务在各级医院及更广泛的医疗体系中的深度整合。此次合作升级将致力于优化工作流程，提升数据互操作性，并最终改善患者护理体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","LU0251142724.SGD","BK4550","BK4588","LU0048573561.USD","LU0006061336.USD","LU2237438978.USD","LU0742534661.SGD","LU1059921491.USD","LH","BK4196","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130176453","title":"异动解读 | 徕博科盘前大涨9.80%，因上调全年业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1130176453","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130176453?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:02","pubTimestamp":1777550561,"startTime":"0","endTime":"0","summary":"徕博科（LH）今日盘前股价大幅上涨9.80%，引起了市场的广泛关注。消息面上，徕博科上调了全年利润和营收预期。该公司公布的季度业绩超出预期，主要得益于诊断检测需求保持稳定。其常规和专科诊断检测业务助力核心业务增长，缓解了药物研发服务部门因生物技术支出放缓带来的冲击。具体来看，徕博科目前预计全年经调整后每股收益将在17.70美元至18.35美元之间，高于此前预测。同时，预计2026年营收将在146.5亿至148.0亿美元之间，同样高于此前预期。公司首席执行官表示，强劲的业绩得益于诊断业务和中央实验室业务的持续增长势头，公司还在扩展专科服务和投资自动化与人工智能领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134162431","title":"财报前瞻｜徕博科本季营收预计增3.16%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1134162431","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134162431?lang=zh_cn&edition=full","pubTime":"2026-04-23 10:32","pubTimestamp":1776911529,"startTime":"0","endTime":"0","summary":"徕博科将于2026年04月30日美股盘前公布最新季度财报，市场预期本季收入与盈利保持温和增长，关注费用效率与新业务协同成效。市场一致预期显示，本季度徕博科营收预计为35.05亿美元，同比增3.16%；息税前利润预计为4.98亿美元，同比增6.03%；调整后每股收益预计为4.09美元，同比增9.40%；上季度官方披露中未见针对本季度的毛利率与净利率量化指引，相关一致预期亦未形成明确口径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜徕博科本季营收预计增3.16%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443137","title":"Labcorp(LH)与AWS合作推出用于阿尔茨海默病研究的AI数据平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443137","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627443137?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:40","pubTimestamp":1776166835,"startTime":"0","endTime":"0","summary":"据介绍，该平台将Labcorp的诊断和基因组数据集与医疗索赔数据相结合，并利用人工智能分析去标识化的医疗保健信息，旨在使研究阿尔茨海默病的科研人员和生物制药公司的数据准备时间从数月缩短至数分钟。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","LU0251131958.USD","LU2237438978.USD","CHAT","BK4196","BK4550","LU0006061336.USD","LU1059921491.USD","AIPO","LU0742534661.SGD","LU0251142724.SGD","LH","LU0048573561.USD","BK4588","BK4585","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131884848","title":"徕博科携手AWS与Datavant推出AI驱动真实世界数据平台，加速阿尔茨海默病研究进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1131884848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131884848?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:06","pubTimestamp":1776164763,"startTime":"0","endTime":"0","summary":"徕博科宣布与亚马逊云服务（AWS）及医疗数据连接技术公司Datavant达成合作，共同推出一款由人工智能驱动的真实世界数据平台。该平台旨在整合与分析大规模现实医疗数据，以显著提升阿尔茨海默病及相关神经退行性疾病的研究效率。\n通过运用先进的人工智能技术，平台能够对去标识化的真实世界数据进行深度挖掘与模式识别，帮助研究人员更快速地识别疾病生物标志物、评估治疗方法的有效性，并优化临床试验设计。这一创新合作有望为阿尔茨海默病的药物研发与精准医疗开辟新的路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006061336.USD","LH","BK4550","BK4196","LU1059921491.USD","LU2237438978.USD","BK4585","BK4588","LU0251131958.USD","LU0742534661.SGD","LU0251142724.SGD","LU0048573561.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149678598","title":"Illumina推出伴行诊断开发服务 助力药企精准医疗布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1149678598","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149678598?lang=zh_cn&edition=full","pubTime":"2026-03-18 21:19","pubTimestamp":1773839987,"startTime":"0","endTime":"0","summary":"全球基因测序巨头Illumina宣布推出面向制药企业的伴行诊断开发服务。伴行诊断作为精准医疗的核心环节，能够通过检测特定生物标志物筛选适合药物治疗的患者群体。值得注意的是，Illumina此次服务的推出正值FDA加速推进个性化医疗审批的窗口期。分析师指出，这一战略举措将帮助Illumina进一步拓展其在医疗健康领域的业务边界。Illumina若能成功打造诊断开发服务平台，将有望在价值数千亿美元的精准医疗市场中占据更重要的位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","ILMN","BK4588","BK4585","BK4535","BK4550","LU0251131958.USD","LU1059921491.USD","LU0742534661.SGD","LU0048573561.USD","LU0006061336.USD","BK4534","BK4196","LH","LU0251142724.SGD","BK4121","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116901456","title":"徕博科深化与PathAI合作 将在全美部署FDA认证数字病理平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1116901456","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116901456?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:03","pubTimestamp":1771848188,"startTime":"0","endTime":"0","summary":"徕博科宣布扩大与人工智能诊断公司PathAI的战略合作，将在美国境内全面推广经美国食品药品监督管理局（FDA）批准的数字病理学平台。此次升级合作将整合双方在诊断技术与算法开发领域的优势资源，通过数字化切片扫描和AI辅助分析系统，提升病理诊断的标准化程度与判读效率。该平台能实现组织样本的云端存储、多重分析及远程会诊功能，预计将优化医疗机构的运营流程，为临床医生提供更精准的定量化诊断依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4585","BK4588","BK4196","LH","LU1059921491.USD","LU0048573561.USD","LU2237438978.USD","LU0251131958.USD","LU0251142724.SGD","LU0006061336.USD","LU0742534661.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128514647","title":"财报前瞻｜徕博科本季度营收预计增7.55%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1128514647","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128514647?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:14","pubTimestamp":1770689695,"startTime":"0","endTime":"0","summary":"徕博科将在2026年02月17日发布最新季度财报，市场关注营收、毛利率与EPS的变化及临床实验室诊断业务延续增长态势。市场一致预期显示，本季度徕博科总营收预计为35.58亿美元，同比增长7.55%；调整后每股收益预计为3.94美元，同比增长16.38%；息税前利润预计为4.87亿美元，同比增长12.56%。多家机构强调本季度EPS与EBIT的增长弹性，认为营收增长7.55%与EPS增长16.38%的预期具备实现基础，若费用率改善进一步兑现，EPS有望高于一致预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜徕博科本季度营收预计增7.55%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143070189","title":"徕博科增加1.25亿美元弹性贷款额度 可在2026年5月29日前随时将总额提升至8.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143070189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143070189?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:43","pubTimestamp":1769722985,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会的文件显示，徕博科（Labcorp）已新增一项1.25亿美元的弹性贷款安排。该协议允许公司在2026年5月29日或之前的任何时间点，将总信贷额度最高提升至8.25亿美元。\n这项弹性机制为徕博科提供了显著的财务灵活性，使其能够根据市场环境变化或战略需求快速调整资金规模。通过设置明确的时间窗口，公司既可规避长期资金沉淀成本，又能确保在关键时刻获得充足流动性支持。\n此次额度扩充延续了徕博科一贯的稳健财务管理策略。在医疗检测行业加速整合的背景下，增强的信贷能力将为潜在并购活动或技术升级提供有力保障，进一步巩固其行业领导地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","BK4550","LU0251142724.SGD","LU1059921491.USD","BK4585","LU2237438978.USD","LU0742534661.SGD","LH","BK4196","LU0006061336.USD","LU0048573561.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146959120","title":"Namsa宣布战略性收购徕博科早期开发医疗器械测试业务精选资产","url":"https://stock-news.laohu8.com/highlight/detail?id=1146959120","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146959120?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:30","pubTimestamp":1767879034,"startTime":"0","endTime":"0","summary":"Namsa公司近日披露，已成功完成对徕博科（Labcorp Holdings Inc）旗下早期开发医疗器械测试业务部分精选资产的战略性收购。此次交易将强化Namsa在医疗器械测试领域的服务能力，拓展其早期开发阶段的业务布局。通过整合优质资源，Namsa旨在提升综合解决方案水平，为全球医疗器械客户提供更高效、专业的支持服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","LU0251131958.USD","BK4196","BK4550","BK4588","LU2237438978.USD","LH","LU0251142724.SGD","LU0048573561.USD","BK4585","LU0742534661.SGD","LU0006061336.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510472920","title":"徕博科2024财年实现净利润7.46亿美元，同比增加96.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510472920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510472920?lang=zh_cn&edition=full","pubTime":"2025-02-10 00:00","pubTimestamp":1739116854,"startTime":"0","endTime":"0","summary":"2月10日，徕博科公布财报，公告显示公司2024财年净利润为7.46亿美元，同比增加96.83%；其中营业收入为130.09亿美元，同比增加6.96%，每股基本收益为8.89美元。从资产负债表来看，徕博科总负债103.13亿美元，其中短期债务11.85亿美元，资产负债比为1.79，流动比率为1.45。机构评级：截至2025年2月10日，当前有16家机构对徕博科目标价做出预测，其中目标均价为271.81美元，其中最低目标价为240.00美元，最高目标价为293.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509777981","title":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由271.00美元调整至260.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509777981","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509777981?lang=zh_cn&edition=full","pubTime":"2025-02-08 06:27","pubTimestamp":1738967224,"startTime":"0","endTime":"0","summary":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由271.00美元调整至260.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08062748031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509773590","title":"杰富瑞投资银行：维持Labcorp Holdings(LH.US)评级，由买入调整至买入评级, 目标价由275.00美元调整至290.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509773590","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509773590?lang=zh_cn&edition=full","pubTime":"2025-02-07 07:26","pubTimestamp":1738884368,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Labcorp Holdings(LH.US)评级，由买入调整至买入评级, 目标价由275.00美元调整至290.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07072648003359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191052054","title":"Labcorp第四季度财报：收入和每股收益超预期，预计2025年将实现强劲增长，分析师重申“表现优异”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1191052054","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191052054?lang=zh_cn&edition=full","pubTime":"2025-02-07 02:24","pubTimestamp":1738866295,"startTime":"0","endTime":"0","summary":"周四，Laboratory Corp报告其2024年第四季度调整后的每股收益为3.45美元，高于去年同期的3.30美元，超出市场预期的3.39美元。销售额同比增长9.8%，达到33.3亿美元，几乎与市场预期的33.1亿美元一致。调整后的季度运营收入为423.2百万美元，占收入的12.7%，而上一年同期为394.9百万美元，占收入的13%。这使得该股票在2025年具有稳定的指导性，并有可能在公司动能持续时获得收益。William Blair重申“表现优异”评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174528505","title":"实验室公司2024年第四季度调整后每股收益为3.45美元，超过预期的3.39美元，销售额为33.3亿美元，超过预期的33.1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174528505","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174528505?lang=zh_cn&edition=full","pubTime":"2025-02-06 19:54","pubTimestamp":1738842871,"startTime":"0","endTime":"0","summary":"相较于去年同期每股收益3.30美元，这是一个4.55%的增长。公司报告季度销售额为33.3亿美元，超过分析师普遍预期的33.1亿美元，超出0.63%。以上内容来自Benzinga Earnings专栏，原文如下：Laboratory Corp  reported quarterly earnings of $3.45 per share which beat the analyst consensus estimate of $3.39 by 1.77 percent. This is a 4.55 percent increase over earnings of $3.30 per share from the same period last year.  The company reported quarterly sales of $3.33 billion which beat the analyst consensus estimate of $3.31 billion by 0.63 percent.  This is a 9.76 percent increase o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149955265","title":"Labcorp预计2025年销售额为138.8亿至140.5亿美元，对比市场预期的137.9亿美元，调整后每股收益为15.60至16.40美元，对比市场预期的16.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149955265","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149955265?lang=zh_cn&edition=full","pubTime":"2025-02-06 19:54","pubTimestamp":1738842859,"startTime":"0","endTime":"0","summary":"2025年指引假设外汇汇率截至2024年12月31日的全年有效。企业层面的指引包括当前预期的资本配置影响，包括收购、股票回购和股息。2024年Labcorp企业的收入为130.1亿美元，诊断实验室收入为101.4亿美元，生物制药实验室服务收入为29.2亿美元。调整后每股收益在2024年为14.57美元，2025年指引为15.60至16.40美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Labcorp预计2025年销售额为138.8亿至140.5亿美元，对比市场预期的137.9亿美元，调整后每股收益为15.60至16.40美元，对比市场预期的16.02美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.labcorp.com","stockEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0305},{"period":"3month","weight":0.0081},{"period":"6month","weight":0.049},{"period":"1year","weight":0.0295},{"period":"ytd","weight":0.0616}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Labcorp Holdings Inc.是特拉华州的一家公司，成立于1971年。公司是一家领先的全球生命科学公司，已在指导患者护理方面深入整合。公司通过其LabCorp诊断（LCD）和Covance药物开发（CDD）部门提供全面的临床实验室和端到端药物开发服务。LabCorp定位于研究和护理交付的融合，以实现更精确和个性化的医疗保健，将世界一流的诊断和药物开发能力结合在一起。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.026972},{"month":2,"riseRate":0.612903,"avgChangeRate":0.024969},{"month":3,"riseRate":0.612903,"avgChangeRate":-0.00762},{"month":4,"riseRate":0.677419,"avgChangeRate":0.052186},{"month":5,"riseRate":0.516129,"avgChangeRate":0.00838},{"month":6,"riseRate":0.59375,"avgChangeRate":0.025423},{"month":7,"riseRate":0.483871,"avgChangeRate":0.008997},{"month":8,"riseRate":0.451613,"avgChangeRate":-0.030248},{"month":9,"riseRate":0.451613,"avgChangeRate":-0.0037},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.003333},{"month":11,"riseRate":0.677419,"avgChangeRate":0.00863},{"month":12,"riseRate":0.709677,"avgChangeRate":0.014463}],"exchange":"NYSE","name":"徕博科","nameEN":"Labcorp Holdings Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"徕博科,LH,徕博科股票,徕博科股票老虎,徕博科股票老虎国际,徕博科行情,徕博科股票行情,徕博科股价,徕博科股市,徕博科股票价格,徕博科股票交易,徕博科股票购买,徕博科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}